EP4010078A4 - Compositions et procédés pour améliorer la mobilisation de récepteur opioïde par des héxadiénoates d'opioïdes et des héxadiénoates éventuellement substitués - Google Patents

Compositions et procédés pour améliorer la mobilisation de récepteur opioïde par des héxadiénoates d'opioïdes et des héxadiénoates éventuellement substitués Download PDF

Info

Publication number
EP4010078A4
EP4010078A4 EP20852037.9A EP20852037A EP4010078A4 EP 4010078 A4 EP4010078 A4 EP 4010078A4 EP 20852037 A EP20852037 A EP 20852037A EP 4010078 A4 EP4010078 A4 EP 4010078A4
Authority
EP
European Patent Office
Prior art keywords
hexadienoates
opioid
compositions
methods
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20852037.9A
Other languages
German (de)
English (en)
Other versions
EP4010078A1 (fr
Inventor
Georgiy Nikonov
Levon Isakulyan
Michael V. Voronkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kappa Pharma LLC
Original Assignee
Kappa Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/540,058 external-priority patent/US11186585B2/en
Application filed by Kappa Pharma LLC filed Critical Kappa Pharma LLC
Publication of EP4010078A1 publication Critical patent/EP4010078A1/fr
Publication of EP4010078A4 publication Critical patent/EP4010078A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20852037.9A 2019-08-11 2020-03-07 Compositions et procédés pour améliorer la mobilisation de récepteur opioïde par des héxadiénoates d'opioïdes et des héxadiénoates éventuellement substitués Pending EP4010078A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885311P 2019-08-11 2019-08-11
US16/540,058 US11186585B2 (en) 2018-08-17 2019-08-14 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
PCT/US2020/021599 WO2021029914A1 (fr) 2019-08-11 2020-03-07 Compositions et procédés pour améliorer la mobilisation de récepteur opioïde par des héxadiénoates d'opioïdes et des héxadiénoates éventuellement substitués

Publications (2)

Publication Number Publication Date
EP4010078A1 EP4010078A1 (fr) 2022-06-15
EP4010078A4 true EP4010078A4 (fr) 2023-08-09

Family

ID=74571142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20852037.9A Pending EP4010078A4 (fr) 2019-08-11 2020-03-07 Compositions et procédés pour améliorer la mobilisation de récepteur opioïde par des héxadiénoates d'opioïdes et des héxadiénoates éventuellement substitués

Country Status (6)

Country Link
EP (1) EP4010078A4 (fr)
JP (1) JP7535569B2 (fr)
CN (1) CN114828961B (fr)
CA (1) CA3149152A1 (fr)
MX (1) MX2022001520A (fr)
WO (1) WO2021029914A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0615756A1 (fr) * 1993-03-15 1994-09-21 National Science Council Esters de nalbuphine, et compositions pharmaceutiques à action prolongée les contenant

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
CN1050130C (zh) 1997-07-04 2000-03-08 卢正堂 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法
DE60001487T2 (de) 2000-04-27 2003-12-24 Oliver Yoa-Pu Hu Polynalbuphinderivat
TWI226239B (en) 2000-05-15 2005-01-11 You-Pu Hu Novel oral pharmaceutical composition containing nalbuphine ester prodrug
EP1309354A2 (fr) 2000-07-27 2003-05-14 Rutgers, The State University Polyesters et polyamides therapeutiques
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
WO2005009377A2 (fr) 2003-07-23 2005-02-03 University Of Kentucky Research Foundation Nouveaux promedicaments assimilables par voie orale
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
US20090192095A1 (en) 2008-01-18 2009-07-30 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
BRPI1015108A2 (pt) 2009-04-02 2016-04-26 Shire Llc pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos
WO2011007247A1 (fr) 2009-07-17 2011-01-20 Llc Shire Nouvel acide amine de carbamate et promedicaments peptidiques d'opioïdes, et utilisations associees
MX2012000980A (es) 2009-07-21 2012-06-12 Nektar Therapeutics Conjugados de agonistas de oligómeros-opioides.
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
CA2795156C (fr) * 2010-04-02 2019-05-14 Alltranz Inc. Prodrogues opioides administrables par voie transdermique, compositions anti-abus et methodes d'utilisation de prodrogues opioides
EP2658523A1 (fr) 2010-12-28 2013-11-06 Euro-Celtique S.A. Combinaison d'un agoniste des opioïdes et d'un antagoniste des opioïdes dans le traitement de la maladie de parkinson
US10017519B2 (en) * 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
CN107427509B (zh) * 2015-08-29 2021-06-15 美德阿利克斯株式会社 含有碱性药物和山梨酸的经皮吸收组成物
US12590065B2 (en) 2017-04-14 2026-03-31 Zevra Therapeutics, Inc. Levorphanol prodrugs and processes for making and using them
US11186585B2 (en) * 2018-08-17 2021-11-30 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0615756A1 (fr) * 1993-03-15 1994-09-21 National Science Council Esters de nalbuphine, et compositions pharmaceutiques à action prolongée les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PENG, X. ET AL.: "Synthesis and Preliminary In vitro Investigation of Bivalent Ligands Containing Homo- and Heterodimeric Pharmacophores at [mu], [delta], and [kappa] Opioid Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 1, 2005, pages 256 - 262, XP055925192, ISSN: 0022-2623, DOI: 10.1021/jm050577x *

Also Published As

Publication number Publication date
JP2022544564A (ja) 2022-10-19
WO2021029914A1 (fr) 2021-02-18
CN114828961A (zh) 2022-07-29
MX2022001520A (es) 2022-07-21
CN114828961B (zh) 2024-03-29
CA3149152A1 (fr) 2021-02-18
EP4010078A1 (fr) 2022-06-15
JP7535569B2 (ja) 2024-08-16

Similar Documents

Publication Publication Date Title
EP4054621A4 (fr) Compositions et procédés de remplacement d'allèles d'adn codé par l'arn
EP3490591A4 (fr) Compositions et procédés pour réduire l'adiposité par inhibition de fsh/fshr
GB201913701D0 (en) Composition of matter
IL290324A (en) Preparations containing tropintide
EP3609664B8 (fr) Compositions d'asphalte et leurs procédés de fabrication
EP3952924A4 (fr) Compositions et méthodes d'administration de produits thérapeutiques
EP3876938A4 (fr) Compositions et procédés d'administration d'antagoniste opioïde
EP3924509A4 (fr) Compositions et méthodes pour la synthèse d'adnc
CA3256071A1 (en) A2-73 crystalline polymorph compositions of matter and methods of use thereof
EP4028058A4 (fr) Compositions et procédés de production et d'utilisation d'anticorps multispécifiques
EP4010078A4 (fr) Compositions et procédés pour améliorer la mobilisation de récepteur opioïde par des héxadiénoates d'opioïdes et des héxadiénoates éventuellement substitués
EP3328364A4 (fr) Nouvelle composition orale à double libération retardée de dexlansoprazole
EP3994168A4 (fr) Anticorps dirigé contre le récepteur de la leptine
EP4077236A4 (fr) Additif à ciment
EP3344593A4 (fr) Compositions et procédés de cimentation de puits
EP3277665A4 (fr) Analogues d'indole en tant qu'antagonistes des récepteurs 5-oxo-ete et procédé d'utilisation de ceux-ci
HK40079201A (en) Methods of producing antibody compositions
HK40065908A (en) Compositions of trofinetide
HK40081744A (en) Recombinase compositions and methods of use
HK40075075A (en) Recombinase compositions and methods of use
HK40080649A (en) Methods of using il-33 antagonists
HK40045736A (en) A2-73 crystalline polymorph compositions of matter and methods of use thereof
HK40061383A (en) Methods for making mixed allergen compositions
HK40073249A (zh) Crf受体拮抗剂及其使用方法
HK40070174A (en) Hmgb1 antagonist

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025360000

Ipc: C07C0219220000

A4 Supplementary search report drawn up and despatched

Effective date: 20230710

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/439 20060101ALI20230704BHEP

Ipc: A61P 25/36 20060101ALI20230704BHEP

Ipc: A61P 25/14 20060101ALI20230704BHEP

Ipc: A61P 17/00 20060101ALI20230704BHEP

Ipc: C07D 489/08 20060101ALI20230704BHEP

Ipc: C07D 489/02 20060101ALI20230704BHEP

Ipc: C07D 221/28 20060101ALI20230704BHEP

Ipc: C07D 221/26 20060101ALI20230704BHEP

Ipc: C07C 219/22 20060101AFI20230704BHEP